1. Home
  2. Our Firm
  3. News
  4. Guggenheim Securities Hires John Pantalena to Expand Leveraged Finance Group

Our Firm

March 29, 2018

Guggenheim Securities Hires John Pantalena to Expand Leveraged Finance Group

NEW YORK – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that John Pantalena has joined the firm as a Senior Managing Director in the firm’s leveraged finance group.

Mr. Pantalena joins Guggenheim from Bank of America Merrill Lynch where he served as Managing Director in the Global Leveraged Finance Investment Banking group, focused on advising energy, power, and natural resources companies. Prior to joining Bank of America Merrill Lynch in 2003, he began his career at Fleet Securities in Boston, MA.

“We are excited that John has joined our leveraged finance team,” said Mark Van Lith, Co-CEO of Guggenheim Securities and Head of Investment Banking. “John’s deep understanding of the leveraged finance markets, particularly in the energy sector, is an important addition to our growing leveraged finance capabilities at Guggenheim. We look forward to his continued success.”

Mr. Pantalena received his B.S. in Economics from Cornell University. He is based in Guggenheim’s New York Office.


About Guggenheim Securities

Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners, a global investment and advisory firm. Guggenheim Securities offers services that fall into four broad categories: Advisory, Financing, Sales and Trading, and Research. Guggenheim Securities is headquartered in New York, with additional offices in Chicago, Boston, Atlanta, Los Angeles, San Francisco, and Houston. For more information, please contact us at GSinfo@GuggenheimPartners.com or 212.518.9200.

About Guggenheim Partners

Guggenheim Partners is a global investment and advisory firm with more than $305 billion1 in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With more than 2,300 professionals based in more than 25 offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting GuggenheimPartners.com and following us on Twitter at twitter.com/guggenheimptnrs.


Media Contact

Ellen Cunningham
Guggenheim Partners
212.518.9578
Ellen.N.Cunningham@GuggenheimPartners.com

 

1Assets under management are as of 12.31.2017 and include consulting services for clients whose assets are valued at approximately $66bn.



November 09, 2020

Guggenheim Securities Hires David Levin to Expand Equity Capital Markets

NEW YORK, NY –  Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that David Levin will join the firm as a Senior Managing Director in Equity Capital Markets, focusing on providing clients with equity and equity-linked financing solutions through the public and alternative equity capital markets.

Read More

October 22, 2020

Guggenheim Securities Hires Joe Niemiec to Expand Middle Market Investment Banking Practice

NEW YORK, NY – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Joe Niemiec has joined the firm as a Senior Managing Director to expand its middle market investment banking coverage and to focus on advising companies in the services and industrials sectors.

Read More

October 05, 2020

Debjit Chattopadhyay Joins Guggenheim Securities as Senior Biotech Analyst

NEW YORK, NY – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Debjit Chattopadhyay will join the firm in December as a Managing Director and Senior Biotech Analyst as part of the Healthcare Equity Research team. Dr. Chattopadhyay’s research focus will be gene therapy and rare diseases.

Read More



© 2020 Guggenheim Partners, LLC. All rights reserved. Guggenheim, Guggenheim Partners and Innovative Solutions. Enduring Values. are registered trademarks of Guggenheim Capital, LLC.